IsoRay Names Jonathan Hunt New Chief Financial Officer

RICHLAND, WASHINGTON – December 3, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced that Jonathan Hunt has been named Chief Financial Officer...

IsoRay Announces First Quarter Fiscal 2019 Financial Results

Year Over Year First Quarter Revenues Increased 29% Double Digit Revenue Increases Year Over Year for Sixth Consecutive Quarter   RICHLAND, WASHINGTON – November 8, 2018 — IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in...
Dr. John Sylvester: “Newer does not necessarily mean better.”

Dr. John Sylvester: “Newer does not necessarily mean better.”

Dr. John Sylvester is considered a pioneer in prostate cancer brachytherapy, having performed over 6,000 prostate brachytherapy procedures to date. It’s no surprise that he is well-versed in its history. “Brachytherapy was [first] used for prostate cancer in 1911 and...